Effects of pneumococcal polysaccharide vaccine: A Synthesis of Findings from 27 Studies

  1. Home
  2. Effects of pneumococcal polysaccharide vaccine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of pneumococcal polysaccharide vaccine: A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of pneumococcal polysaccharide vaccine: A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Pneumococcal vaccines are important preventative measures for protecting against pneumococcal infections. While various studies have been conducted, the understanding of their efficacy and safety is deepening. Several studies indicate that revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is safe and immunogenic even in the elderly. 27 Moreover, PPSV23 has been proven to be a safe and effective vaccine for kidney transplant recipients, whose immune systems are compromised due to immunosuppressant use. 3 Additionally, a new 20-valent pneumococcal conjugate vaccine (PCV20) demonstrates safety and immunogenicity in the elderly, potentially offering broader protection against pneumococcal serotypes compared to the existing 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23. 17 However, interpreting PPSV23 efficacy results can be challenging. 12 While some studies show PPSV23 to be effective in preventing pneumonia in the elderly, others indicate limited effectiveness. 14 , 13 Furthermore, PPSV23 might exhibit reduced efficacy in patients whose immune systems are weakened due to immunosuppressant use. 8 Pneumococcal vaccines are crucial preventative measures, particularly for individuals at high risk of pneumococcal infections, such as the elderly and immunocompromised individuals. However, vaccines are not foolproof, and individuals can still contract pneumococcal infections even after vaccination. 10 To maximize the efficacy of pneumococcal vaccines while ensuring safety, selecting and administering appropriate vaccines based on individual patient circumstances is essential.

Benefits and Risks

Benefit Summary

Pneumococcal vaccines have demonstrated their safety and effectiveness in numerous studies, making them a valuable preventative measure against pneumococcal infections. 27 , 3 , 17 Vaccination is particularly crucial for individuals at increased risk of pneumococcal infections, such as the elderly and immunocompromised individuals. The new 20-valent pneumococcal conjugate vaccine (PCV20) holds the promise of offering broader protection against a wider range of pneumococcal serotypes compared to previous vaccines. 17 Pneumococcal vaccination can effectively reduce the risk of severe infections caused by pneumococcus. 8

Risk Summary

While generally considered safe, pneumococcal vaccines, like all vaccines, carry the potential for side effects. 26 Side effects are typically mild and temporary. Common side effects include pain and swelling at the injection site, and fever. 19 Serious side effects are rare but possible. Allergic reactions, such as anaphylaxis, can occur after vaccination. 18 Prior to vaccination, it is important to consult with a physician regarding any history of allergies or other health concerns.

Comparison between Studies

Commonalities

Numerous studies have consistently shown that pneumococcal vaccines are an effective preventative measure against pneumococcal infections. 27 , 3 , 17 , 12 , 22 , 25 , 2 , 7 , 20 , 15 , 24 , 11 , 5 , 8 , 9 , 19 , 1 , 10 , 26 , 4 , 6 , 18 , 14 , 13 , 21 , 16 Furthermore, numerous studies consistently indicate that pneumococcal vaccines are generally safe. 26

Differences

Research findings on pneumococcal vaccine efficacy and safety exhibit some differences. 12 , 14 , 13 For instance, interpreting PPSV23 efficacy results can be challenging. 12 While some studies demonstrate PPSV23 efficacy in preventing pneumonia in the elderly, others suggest limited effectiveness. 14 , 13 Additionally, PPSV23 might have reduced efficacy in patients whose immune systems are compromised due to immunosuppressant use. 8 These variations could be attributed to differences in study design, target populations, or even changes in circulating pneumococcal strains. 10 Furthermore, pneumococcal vaccine efficacy and safety can vary depending on the vaccine type and vaccination schedule. 18 Therefore, considering these differences is crucial when interpreting research findings on pneumococcal vaccine efficacy and safety.

Consistency and Inconsistencies in the Findings

Research findings regarding pneumococcal vaccine efficacy exhibit both consistency and inconsistencies. 12 While some studies indicate PPSV23 efficacy in preventing pneumonia in the elderly, others suggest limited effectiveness. 14 , 13 These inconsistencies could be explained by various factors, including study design, target populations, and even changes in the prevalence of pneumococcal strains. 10 Further research is needed to gain a more comprehensive understanding of pneumococcal vaccine efficacy.

Considerations for Real-World Application

Pneumococcal vaccines are essential preventative measures for individuals at increased risk of pneumococcal infections. 10 However, vaccination does not guarantee protection against pneumococcal infections for all individuals. 26 Furthermore, vaccines mitigate the risk of pneumococcal infections rather than eliminating it completely. 8 Individuals at high risk of pneumococcal infections should continue practicing preventive measures such as handwashing and gargling even after vaccination.

Limitations of Current Research

Research on pneumococcal vaccine efficacy remains incomplete. 10 Interpreting PPSV23 efficacy results can be particularly challenging. 12 Moreover, pneumococcal vaccine efficacy can vary depending on the target population, vaccine type, and vaccination schedule. 18 Therefore, further research is needed to gain a deeper understanding of pneumococcal vaccine efficacy.

Future Research Directions

To gain a more comprehensive understanding of pneumococcal vaccine efficacy, the following research is needed: 21 * Conducting larger-scale studies on PPSV23 efficacy. 12 * Researching PPSV23 efficacy in various target populations. 14 * Assessing the efficacy and safety of new pneumococcal vaccines. 17 * Investigating the relationship between pneumococcal vaccine scheduling and efficacy. 9 * Researching methods for enhancing pneumococcal vaccine efficacy. 16

Conclusion

Pneumococcal vaccines are an important preventative measure against pneumococcal infections. 8 Numerous studies have consistently shown that pneumococcal vaccines are generally safe and effective. 19 However, vaccination does not guarantee protection against pneumococcal infections for all individuals. 10 Individuals at high risk of pneumococcal infections should continue practicing preventive measures such as handwashing and gargling even after vaccination. 26 To maximize the efficacy of pneumococcal vaccines while ensuring safety, selecting and administering appropriate vaccines based on individual patient circumstances is essential. 18 Research on pneumococcal vaccines needs to continue in the future.

Literature analysis of 27 papers
Positive Content
24
Neutral Content
2
Negative Content
1
Article Type
6
3
3
1
27
1.

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.

Author: WatsonLorna, WilsonBrenda J, WaughNorman

Reduces mortality
Reduces pneumococcal bacteremia
Reduces pneumonia

Pneumococcal vaccination showed no benefit in industrialised populations other than for pneumococcal bacteraemia. Clear benefit was demonstrated for mortality and all-cause pneumonia in non-industrial populations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

2.

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells.

Author: ClutterbuckElizabeth A, LazarusRajeka, YuLy-Mee, BowmanJaclyn, BatemanElizabeth A L, DiggleLinda, AngusBrian, PetoTim E, BeverleyPeter C, MantDavid, PollardAndrew J

Pneumococcal infection prevention

The 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP) is commonly given to adults over 65, but its effectiveness is limited and revaccination leads to weaker antibody responses. It is unclear if pneumococcal polysaccharide-protein conjugated vaccines (PCV), which are highly effective in infants, offer any advantages over 23vP for adults.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.

Author: ErikssonMari, KäyhtyHelena, SahaHeikki, LahdenkariMika, KoskinenPetri, MäkisaloHeikki, AnttilaVeli-Jukka

Improved immunogenicity
Safe revaccination

A study comparing 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPV23) in dialysis patients found that PCV13 was more immunogenic and safe. The PCV13 group showed significantly higher geometric mean concentrations (GMCs) for 9/13 serotypes and geometric mean titers (GMTs) for 4/13 serotypes after the first vaccination. Revaccination with PCV13 six months after transplantation was also immunogenic and safe.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.

Author: NishikawaAlvaro Mitsunori, SartoriAna Marli Christovam, MainardiGiulia Marcelino, FreitasAngela Carvalho, ItriaAlexander, NovaesHillegonda Maria Dutilh, de SoárezPatrícia Coelho

Cost-effectiveness

Economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) suggest it is cost-effective for adults aged 60 years and older.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

5.

A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014.

Author: HamaguchiMegumi, TsubataYukari, YoshiharaKen, NakaoMika, AmanoYoshihiro, NakashimaKazuhisa, HottaTakamasa, OkimotoTamio, HamaguchiShunichi, SutaniAkihisa, IsobeTakeshi

Pneumococcal disease prevention

This study investigates the onset of pneumococcal pneumonia in general practice in Izumo, Shimane Prefecture, Japan, after the implementation of a public subsidy for PPSV23 inoculation in November 2012.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.

Author: van AalstMariëlle, LangedijkAnnefleur C, SpijkerRené, de BreeGodelieve J, GrobuschMartin P, GoorhuisAbraham

Infection prevention
Pneumococcal vaccination
Immunosuppressant side effects
Vaccination effectiveness unknown

People with weakened immune systems are at higher risk for pneumonia caused by Streptococcus pneumoniae bacteria. Although vaccination is recommended, it is not clear how well it works in these people. This study reviewed research on the effectiveness of pneumococcal vaccination in people taking immunosuppressive drugs. More research is needed to understand how well these vaccines work in this group.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

9.

Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.

Author: AzumaMomoyo, OishiKazunori, AkedaYukihiro, MorinoSaeko, MotokiYumi, HanibuchiMasaki, NishiokaYasuhiko

immunogenicity
safety

This open-label study compared the safety and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) at intervals of 0.5 years and 1 year in adults aged ≥ 65 years.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.

Author: WijayasriShinthuja, HillierKelty, LimGillian H, HarrisTara M, WilsonSarah E, DeeksShelley L

Pneumococcal disease prevention

This study examines the epidemiology and serotype distribution of invasive pneumococcal disease (IPD) in Ontario in the context of provincial immunization programs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.

Author: SolankiBhagirath B, JuergensChristine, ChopadaManojkumar B, SupePravin, SundaraiyerVani, Le Dren-NarayaninNatacha, CutlerMark W, GruberWilliam C, ScottDaniel A, Schmoele-ThomaBeate

Pneumococcal disease prevention

A study in India evaluated the safety and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged 50 to 65 years. The vaccine was well tolerated and elicited robust immune responses against all 13 pneumococcal serotypes.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Rethinking results from the Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial.

Author: GessnerBradford D, TheilackerChristian, JodarLuis

Protection from pneumococcal pneumonia
Data quality issues

This study reviewed a clinical trial that was used to support the use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults. The authors argue that the trial had serious flaws that affect its usefulness in evaluating pneumococcal vaccines.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan.

Author: YamanaHayato, OnoSachiko, MichihataNobuaki, UemuraKohei, JoTaisuke, YasunagaHideo

Reduced pneumonia risk

This study found that the 23-valent pneumococcal polysaccharide vaccine (PPV23) was associated with a decreased incidence of hospitalization with pneumonia in older adults. However, vaccine effectiveness was significant in those aged 65 to 85 years but not in the older population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

14.

Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.

Author: SuzukiKanzo, KondoKyoko, WashioMasakazu, NakashimaKei, KanSakae, ImaiSeiichiro, YoshimuraKunihiko, OtaChiharu, OhfujiSatoko, FukushimaWakaba, HirotaYoshio

Pneumococcal CAP prevention

PPSV23 vaccination is effective in reducing the incidence of pneumococcal pneumonia in older individuals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.

Author: CannonKevin, ElderCharles, YoungMariano, ScottDaniel A, ScullyIngrid L, BaugherGary, PengYahong, JansenKathrin U, GruberWilliam C, WatsonWendy

Pneumococcal disease prevention

A 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against pneumococcal disease. This study evaluated the safety and immunogenicity of PCV20 in adults 65 years and older who had previously received pneumococcal vaccines. The study aimed to assess the vaccine's effectiveness in providing additional protection against serotypes not covered by previous vaccines and to evaluate its safety profile in this population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.

Author: GrabarSophie, GrohMatthieu, BahuaudMathilde, Le GuernVéronique, Costedoat-ChalumeauNathalie, MathianAlexis, HanslikThomas, GuillevinLoïc, BatteuxFrédéric, LaunayOdile,

Pneumococcal disease prevention

Sequential immunization with the 7-valent pneumococcal conjugate (PnCj) vaccine followed by the 23-valent polysaccharide (PPS) vaccine was more effective and safe than PPS vaccination alone in patients with systemic lupus erythematosus (SLE).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.

Author: OhshimaNobuharu, AkedaYukihiro, NagaiHideaki, OishiKazunori

Increased IgG
Vaccine safety
Local reactions
Systemic reactions

This study assessed the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in a cohort of 16 elderly patients with chronic lung diseases. It found that the vaccine induced significant increases in serotype-specific IgG and opsonization index after all three vaccinations. While local and systemic reactions were more frequent after the second and third vaccinations, no serious systemic reactions were observed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.

Author: DirmesropianS, WoodJ G, MacIntyreC R, BeutelsP, McIntyreP, MenziesR, ReyesJ F, ChenC, NewallA T

Improved pneumococcal prevention
PPV23 replacement

This study discusses the replacement of a single dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) in older Australian adults.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation.

Author: Garcia GarridoHannah M, HaggenburgSabine, SchoordijkMarieke C E, MeijerEllen, TanckMichael W T, HazenbergMette D, RuttenCaroline E, de BreeGodelieve J, NurErfan, MeekBob, GrobuschMartin P, GoorhuisAbraham

This prospective cohort study investigated the immunogenicity of a 5-dose pneumococcal vaccination schedule in adult allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. While the response to PCV13 was reasonable, the response to PPSV23 serotypes was poor, leading to insufficient overall seroprotection. Further research is needed to develop more effective pneumococcal vaccination strategies for allo-HSCT recipients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.

Author: Ofori-AnyinamOpokua, Leroux-RoelsGeert, DrameMamadou, AerssensAnnelies, MaesCathy, AmanullahArshad, SchuindAnne, LiPing, JainVarsha K, InnisBruce L

improved uptake
vaccine effectiveness
pain

This phase 3, placebo-controlled, observer-blind trial compared co-administration versus separate administration of an inactivated quadrivalent influenza vaccine (IIV4) with a 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults at high risk of complications from influenza and pneumococcal infection. The study found that co-administration did not reduce antibody responses to either vaccine and may improve vaccine uptake.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

23.

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study.

Author: von MollendorfClaire, UlziibayarMukhchuluun, GessnerBradford D, DoLien Anh Ha, NguyenCattram D, BeavonRohini, SuuriBujinlkham, LuvsantserenDashtseren, NarangerelDorj, JenneyAdam, DunneEileen M, SatzkeCatherine, DarmaaBadarchiin, MungunTuya, MulhollandE Kim

Pneumonia prevention

Pneumococcal conjugate vaccines (PCVs) are effective in preventing pneumococcal pneumonia, but their impact on adult pneumonia in developing countries requires further study. This research aims to investigate the association between childhood PCV vaccination and adult pneumonia trends in Mongolia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.

Author: KimJong Hun, ChunByung Chul, SongJoon Young, KimHyo Youl, BaeIn-Gyu, KimDong-Min, ChoiYoung Hwa, JunYoon Hee, ChoiWon Suk, KangSeong Hee, KwonHyun Hee, JeongHye Won, KeeSae Yoon, HurJian, ChungJin Won, YoonYoung Kyung, SohnJang Wook, YangKyung Sook, KimMin Ja

Pneumococcal disease prevention

This study estimated the direct effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal diseases in the elderly population. The study challenged the previously reported direct effectiveness of PPV23 in the elderly population, considering the increasing herd effects and serotype replacement by childhood pneumococcal protein conjugated vaccines (PCVs) worldwide.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Altered immunogenicity of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes who revealed lower responses to concomitant administration of BIKEN varicella zoster vaccine: Results of post hoc analysis of a randomized double-blind trial.

Author: HataAtsuko, IshiokaTaisei, OishiKazunori, KatayamaToshiro, OhkuboTakayoshi

VZV immunity
vaccine safety
poor response

This double-blind randomized controlled study of 52 elderly patients with diabetes assessed cell-mediated immunity and safety of BIKEN varicella-zoster vaccine (BVZV). Cellular and humoral responses to VZV at 3 months after BVZV and 23-valent polysaccharide pneumococcal vaccine (PPSV23) vaccination elicited poor results. Post-hoc analyses assessed the effects of immunogenicity of PPSV23.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

27.

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.

Author: KawakamiKenji, KishinoHiroyuki, KanazuShinichi, TakahashiKenichi, IinoTomoharu, SawataMiyuki, MuseyLuwy

Immunogenic revaccination
Well-tolerated

Revaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 5 years after the initial vaccination was found to be immunogenic and well-tolerated in elderly individuals ≥70 years of age, regardless of the time interval between the initial vaccination and revaccination.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.